Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology
Awards, Training and Qualifications
- MB BS University of London 1990
- DPhil University of Oxford 1998
- FRCP Royal College of Physicians, London 2006
MB BS, DPhil, FRCP
Head of Clinical Neurology and Professor of Motor Neuron Biology
The main aim of my research is to overcome the barriers to translational medicine in neurodegenerative diseases by identifying the earliest pathological pathways activated in motor neuron disease in order to define the most therapeutically tractable areas for drug therapy and to apply these findings to clinical studies in patients. In particular, we aim to understand why ubiquitously expressed proteins involved in RNA processing and trafficking (SMN, FUS and TDP-43) are critically important for motor neuron integrity. Our research encompasses basic molecular studies in model systems in the laboratory and tissue from patients. A major biomarkers study in ALS (BioMOx), led by Dr Martin Turner is developing ways of tracking disease using imaging and proteomics, but is also providing important new insights into basic disease mechanisms.
ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.
de Majo M. et al, (2018), Neurobiol aging, 71, 266.e1 - 266.e10
Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction.
Gordon D. et al, (2018), Neurobiol dis
Towards a TDP-43-Based Biomarker for ALS and FTLD.
Feneberg E. et al, (2018), Mol neurobiol, 55, 7789 - 7801
Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation.
Wong MMK. et al, (2018), Acta neuropathol commun, 6
Frequency and signature of somatic variants in 1461 human brain exomes.
Wei W. et al, (2018), Genet med